FeesSafety
Pluang+

Setmelanotide shows sustained BMI reduction in acquired hypothalamic obesity after 2 years, new diagnostic criteria unveiled

Market News
16 Nov 2026, 23:00 WIB
GlobeNewsWire
View Source
Bullish
Setmelanotide shows sustained BMI reduction in acquired hypothalamic obesity after 2 years, new diagnostic criteria unveiled

Rhythm Pharmaceuticals presented two-year Phase 3 trial data at ObesityWeek 2026 showing that setmelanotide therapy sustained significant BMI reductions in patients with acquired hypothalamic obesity (HO). A global expert panel also introduced a consensus definition and diagnostic criteria for this rare condition, aiming to improve diagnosis and patient care. The trial included 125 patients, with continuous treatment showing an average BMI reduction of 18.8%. Setmelanotide is approved in the US, EU, and UK for treating HO and certain genetic obesity disorders. This progress supports better recognition and treatment options for patients with this challenging disease.

Rhythm Pharmaceuticals data presentation is the subject, with this snapshot from Pluang's health sector on Nov 17, 2026 at 03:31 WIB: Out of 150 US health stocks, 31 rose and 118 fell. Notable movers include ARWR at USD 44.78 (-6.28%), SANA at USD 1.90 (-6.19%) with 100% buy orders, and MESO at USD 12.47 (-6.03%).

More News

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney's fiscal Q4 report, due November 17, is expected to show strong growth with analysts forecasting over 50% earnings per share (EPS) growth and more than 12% revenue increase. Streaming revenue rose 11% last quarter with margins hitting double d...

Company Fundamentals
Bullish
2 hours ago
Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox has launched a new Australia realm on Amazon Web Services (AWS) in the Sydney region, providing Australian government agencies and enterprises a local option for managing DNS, DHCP, and IP address management (DDI) with enhanced security. Thi...

Market News
Bullish
2 hours ago
European Commission approves RASONQUE for metastatic pancreatic cancer treatment

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identifie...

Market News
Bullish
3 hours ago
SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE, a European leader in multi-technical services, has acquired Dutch company Duflex B.V. to enhance its industrial automation, machine building, and robotics capabilities. Duflex, with 26 employees and €8 million revenue in 2025, specializes in ta...

Company Fundamentals
Bullish
4 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel Développement SAS disclosed that it repurchased a total of 3,878 of its own shares between November 9 and November 13, 2026. The average purchase price during this period was approximately €34.67 per share. This buyback is part of an authorized...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App